Rapid optical determination of β-lactamase and antibiotic activity

BMC Microbiology

Volumn 14, Issue 1, 2014, Pages

  Khan, Shazia ^a   Sallum, Ulysses W ^a,c   Zheng, Xiang ^a,d   Nau, Gerard J ^b   Hasan, Tayyaba ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Partners Research Ventures and Licensing   (United States)

^d PFIZER INC   (United States)

Author keywords

Antibiotic activity; Antibiotic susceptibility; Cefazolin; Cephalosporin; Fluorescence; Fluorophore; Quenching; Staphylococcus; lactam; lactamase

Indexed keywords

BETA LACTAMASE; CEFAZOLIN; CEFEPIME; CEFOXITIN; NITROCEFIN;

ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; DISK DIFFUSION; DRUG STRUCTURE; ENZYME ASSAY; ENZYME SYNTHESIS; EPSILOMETER TEST; FLUORESCENCE ANALYSIS; GOLD STANDARD; NITROCEFIN DISK TEST; NONHUMAN; OPTICS; PRESCRIPTION; RAPID OPTICAL DETERMINATION; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CEFAZOLIN; FLUOROMETRY; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84898809092     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-14-84     Document Type: Article

References (75)

1. Antibiotic resistance in the intensive care unit. Kollef MH, Fraser VJ, Ann Intern Med 2001 134 4 298 314 10.7326/0003-4819-134-4-200102200-00014 11182841
2. Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia. Rello J, Eur Respir Rev 2007 103 33 39
3. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Cosgrove SE, Clin Infect Dis 2006 42 Suppl 2 82 S89 16355321
4. Levy SB, The antibiotic paradox: How the misuse of antibiotics destroys their curative powers Cambridge, MA: Perseus Publishing 2 2002
5. Microbial resistance to antibiotics: An evolving and persistent problem. Levy SB, Lancet 1982 2 8289 83 88 6123819
6. Correlation between consumption of antimicrobials in humans and development of resistance in bacteria. Cristino JM, Int J Antimicrob Agents 1999 12 3 199 202 10.1016/S0924-8579(99)00052-7 10461837
7. Antibiotic resistance: the ongoing challenge for effective drug therapy. Deasy J, JAAPA 2009 22 3 18 22
8. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of america. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J, Clin Infect Dis 2009 48 1 1 12 19035777
9. Current concepts in laboratory testing to guide antimicrobial therapy. Jenkins SG, Schuetz AN, Mayo Clin Proc 2012 87 3 290 308 10.1016/j.mayocp.2012. 01.007 22386185
10. Antibiotic resistance-the need for global solutions. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli M, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O, Lancet Infect Dis 2013 13 12 1057 1098 10.1016/S1473-3099(13) 70318-9 24252483
11. DeBellis RJ, Zdanawicz M, Bacteria Battle Back: Addressing Antibiotic Resistance Boston, MA: Massachusetts College of Pharmacy and Health Science November 2000. http://www.tufts.edu/med/apua/research/completed-projects-5- 1888322820.pdf.
12. Multiple mechanisms of methicillin resistance and improved methods for detection in clinical isolates of Staphylococcus aureus. de Lencastre H, Sa Figueiredo AM, Urban C, Rahal J, Tomasz A, Antimicrob Agents Chemother 1991 35 4 632 639 10.1128/AAC.35.4.632 2069369
13. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. Le Thomas I, Couetdic G, Clermont O, Brahimi N, Plesiat P, Bingen E, J Antimicrob Chemother 2001 48 4 553 555 10.1093/jac/48.4.553 11581237
14. Serine beta-lactamases and penicillin-binding proteins. Ghuysen JM, Annu Rev Microbiol 1991 45 37 67 10.1146/annurev.mi.45.100191.000345 1741619
15. Resistance to beta-lactam antibiotics: resistance mediated by beta-lactamase. Dyke KGH, Gregory PD, The Staphylococci in Human Disease Churchill Livingstone, Crossley KB, Archer GL, 1 1996 136 157
16. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Bush K, Jacoby GA, Medeiros AA, Antimicrob Agents Chemother 1995 39 6 1211 1233 10.1128/AAC.39.6.1211 7574506
17. Beta-Lactamases in laboratory and clinical resistance. Livermore DM, Clin Microbiol Rev 1995 8 4 557 584 8665470
18. Mechanisms of resistance and clinical relevance of resistance to beta-lactams, glycopeptides, and fluoroquinolones. Rice LB, Mayo Clin Proc 2012 87 2 198 208 10.1016/j.mayocp.2011.12.003 22305032
19. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. Rice LB, J Infect Dis 2008 197 8 1079 1081 10.1086/533452 18419525
20. Staphylococcus aureus endocarditis: a consequence of medical progress. Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS, Investigators ICE, JAMA 2005 293 24 3012 3021 10.1001/jama.293.24.3012 15972563
21. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Miro JM, Anguera I, Cabell CH, Chen AY, Stafford JA, Corey GR, Olaison L, Eykyn S, Hoen B, Abrutyn E, Raoult D, Bayer A, Fowler VG Jr, International Collaboration on Endocarditis Merged Database Study G, Clin Infect Dis 2005 41 4 507 514 10.1086/431979 16028160
22. Penicillinase production and intrinsic resistance to penicillins in methicillin-resistant cultures of Staphylococcus aureus. Dyke KG, J Med Microbiol 1969 2 3 261 278 10.1099/00222615-2-3-261 5405709
23. Methicillin-resistant staphylococci 1965-75. Kayser FH, Lancet 1975 2 7936 650 653 52016
24. Studies on recently isolated cultures of methicillin-resistant Staphylococcus aureus. Lacey RW, Stokes A, J Gen Microbiol 1979 114 2 329 339 10.1099/00221287-114-2-329 261529
25. Antibiotic susceptibility and phage-type pattern of Staphylococcus aureus strains isolated from patients in general practice compared to strains from hospitalized patients. Rosdahl VT, Westh H, Jensen K, Scand J Infect Dis 1990 22 3 315 320 10.3109/00365549009027053 2142539
26. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. Hartman BJ, Tomasz A, J Bacteriol 1984 158 2 513 516 6563036
27. Decreased affinity of a penicillin-binding protein for β-lactam antibiotics in a clinical isolate of Staphylococcus aureus resistant to methicillin. Hayes MV, Curits NAC, Wyke AW, Ward JB, FEMS Microbiol Lett 1981 10 2 119 122
28. Regulation of penicillin-binding protein activity: description of a methicillin-inducible penicillin-binding protein in Staphylococcus aureus. Rossi L, Tonin E, Cheng YR, Fontana R, Antimicrob Agents Chemother 1985 27 5 828 831 10.1128/AAC.27.5.828 3848293
29. The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins. McDougal LK, Thornsberry C, J Clin Microbiol 1986 23 5 832 839 3011847
30. Penicillinase production in Staphylococcus aureus strains of clinical importance. Rosdahl VT, Dan Med Bull 1986 33 4 175 184 2943562
31. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA, Kawasaki D, Committee on Rheumatic Fever E, Circulation 2005 111 23 394 e434 10.1161/CIRCULATIONAHA.105. 165564 15956145
32. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. Wilson WR, Karchmer AW, Dajani AS, Taubert KA, Bayer A, Kaye D, Bisno AL, Ferrieri P, Shulman ST, Durack DT, JAMA 1995 274 21 1706 1713 10.1001/jama.1995. 03530210060032 7474277
33. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Nannini EC, Stryjewski ME, Singh KV, Bourgogne A, Rude TH, Corey GR, Fowler VG Jr, Murray BE, Antimicrob Agents Chemother 2009 53 8 3437 3441 10.1128/AAC.00317-09 19487449
34. Use of a heavy inoculum in the in vitro evaluation of the anti-staphylococcal activity of 19 cephalosporins. Laverdiere M, Welter D, Sabath LD, Antimicrob Agents Chemother 1978 13 4 669 675 10.1128/AAC.13.4.669 352261
35. Inoculum effect. Brook I, Rev Infect Dis 1989 11 3 361 368 10.1093/clinids/11.3.361 2664999
36. Determination of an inoculum effect with various cephalosporins among clinical isolates of methicillin-susceptible Staphylococcus aureus. Nannini EC, Stryjewski ME, Singh KV, Rude TH, Corey GR, Fowler VG Jr, Murray BE, Antimicrob Agents Chemother 2010 54 5 2206 2208 10.1128/AAC.01325-09 20211890
37. Unsuccessful treatment of staphylococcal endocarditis with cefazolin. Bryant RE, Alford RH, JAMA 1977 237 6 569 570 10.1001/jama.1977.03270330059022 576284
38. Cefazolin therapy for Staphylococcus aureus bacteremia. Fernandez-Guerrero ML, de Gorgolas M, Clin Infect Dis 2005 41 1 127 10.1086/430833 15937778
39. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Nannini EC, Singh KV, Murray BE, Clin Infect Dis 2003 37 9 1194 1198 10.1086/379021 14557964
40. Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. Quinn EL, Pohlod D, Madhavan T, Burch K, Fisher E, Cox F, J Infect Dis 1973 128 Suppl 386 S389 4744022
41. CLSI, Performance standards for antimicrobial susceptibility testing; Twenty-second informational supplement; CLSI document M100-S22 Wayne, Pennsylvania, USA: Clinical and Laboratory Standards Institute 2012
42. CLSI, Performance standards for antimicrobial disk susceptibility tests; approved standard-eleventh edition. CLSI document M02-A11 Wayne, Pennsylvania, USA: Clinical and Laboratory Standards Institute 2012
43. Evaluation of the E test, a novel method of quantifying antimicrobial activity. Brown DF, Brown L, J Antimicrob Chemother 1991 27 2 185 190 10.1093/jac/27.2.185 2055809
44. Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues. Thomson KS, J Clin Microbiol 2010 48 4 1019 1025 10.1128/JCM.00219-10 20181902
45. Detection of gram-negative beta-lactamase producing pathogens in the clinical lab. Thomson KS, Curr Pharm Des 2013 19 2 250 256 10.2174/ 138161213804070249 22894616
46. Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases. Katsanis GP, Spargo J, Ferraro MJ, Sutton L, Jacoby GA, J Clin Microbiol 1994 32 3 691 696 8195380
47. Production of KPC-2 alone does not always result in beta-lactam MICs representing resistance in gram-negative pathogens. Roth AL, Thomson KS, Lister PD, Hanson ND, J Clin Microbiol 2012 50 12 4183 4184 10.1128/JCM.02194-12 22972823
48. CLSI, Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement; CLSI document M100-S21 Wayne, Pennsylvania, USA: Clinical and Laboratory Standards Institute 2011
49. Exploiting a Bacterial DrugResistance Mechanism: A LightActivated Construct for the Destruction of MRSA. Zheng X, Sallum UW, Verma S, Athar H, Evans CL, Hasan T, Angew Chem Int Ed Engl 2009 121 12 2182 2185 10.1002/ange.200804804
50. Rapid functional definition of extended spectrum beta-lactamase activity in bacterial cultures via competitive inhibition of fluorescent substrate cleavage. Sallum UW, Zheng X, Verma S, Hasan T, Photochem Photobiol 2010 86 6 1267 1271 10.1111/j.1751-1097.2010.00801.x 20854415
51. Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter. Zlokarnik G, Negulescu PA, Knapp TE, Mere L, Burres N, Feng L, Whitney M, Roemer K, Tsien RY, Science 1998 279 5347 84 88 10.1126/science.279.5347.84 9417030
52. beta-lactamase as a marker for gene expression in live zebrafish embryos. Raz E, Zlokarnik G, Tsien RY, Driever W, Dev Biol 1998 203 2 290 294 10.1006/dbio.1998.8999 9808780
53. Novel fluorogenic substrates for imaging beta-lactamase gene expression. Gao W, Xing B, Tsien RY, Rao J, J Am Chem Soc 2003 125 37 11146 11147 10.1021/ja036126o 16220906
54. Cell-permeable near-infrared fluorogenic substrates for imaging beta-lactamase activity. Xing B, Khanamiryan A, Rao J, J Am Chem Soc 2005 127 12 4158 4159 10.1021/ja042829+ 15783183
55. Correlation of penicillin minimum inhibitory concentrations and penicillin zone edge appearance with staphylococcal beta-lactamase production. Gill VJ, Manning CB, Ingalls CM, J Clin Microbiol 1981 14 4 437 440 6974738
56. Cefepime: a new fourth-generation cephalosporin. Okamoto MP, Nakahiro RK, Chin A, Bedikian A, Gill MA, Am J Hosp Pharm 1994 51 4 463 477 quiz 541-462 8017411
57. [Cefepime (maxipime), large spectrum 4th generation cephalosporin, resistant to beta-lactamases]. Angelescu M, Apostol A, Chirurgia 2001 96 6 547 552 12731231
58. A practical guide to the treatment of complicated skin and soft tissue infections. Fung HB, Chang JY, Kuczynski S, Drugs 2003 63 14 1459 1480 10.2165/00003495-200363140-00003 12834364
59. Once-daily cefazolin and probenecid for skin and soft tissue infections. Cox VC, Zed PJ, Ann Pharmacother 2004 38 3 458 463 10.1345/aph.1D251 14970368
60. Multicenter evaluation of BBL CHROMagar MRSA medium for direct detection of methicillin-resistant Staphylococcus aureus from surveillance cultures of the anterior nares. Flayhart D, Hindler JF, Bruckner DA, Hall G, Shrestha RK, Vogel SA, Richter SS, Howard W, Walther R, Carroll KC, J Clin Microbiol 2005 43 11 5536 5540 10.1128/JCM.43.11.5536-5540.2005 16272482
61. Evaluation of a cefoxitin 30 microg disc on Iso-Sensitest agar for detection of methicillin-resistant Staphylococcus aureus. Skov R, Smyth R, Clausen M, Larsen AR, Frimodt-Moller N, Olsson-Liljequist B, Kahlmeter G, J Antimicrob Chemother 2003 52 2 204 207 10.1093/jac/dkg325 12837728
62. Results of disk diffusion testing with cefoxitin correlate with presence of mecA in Staphylococcus spp. Swenson JM, Tenover FC, Cefoxitin Disk Study G, J Clin Microbiol 2005 43 8 3818 3823 10.1128/JCM.43.8.3818-3823.2005 16081917
63. Evaluation of different methods for detecting methicillin (oxacillin) resistance in Staphylococcus aureus. Velasco D, del Mar TM, Cartelle M, Beceiro A, Perez A, Molina F, Moure R, Villanueva R, Bou G, J Antimicrob Chemother 2005 55 3 379 382 10.1093/jac/dki017 15722394
64. Phenotypic detection of methicillin resistance in Staphylococcus aureus by disk diffusion testing and Etest on Mueller-Hinton agar. Skov R, Smyth R, Larsen AR, Bolmstrom A, Karlsson A, Mills K, Frimodt-Moller N, Kahlmeter G, J Clin Microbiol 2006 44 12 4395 4399 10.1128/JCM.01411-06 17050809
65. The inoculum effect with gram-negative bacteria in vitro and in vivo. Davey PG, Barza M, J Antimicrob Chemother 1987 20 5 639 644 10.1093/jac/20.5.639 3429369
66. Implications of the inoculum effect. Soriano F, Ponte C, Rev Infect Dis 1990 12 2 369 10.1093/clinids/12.2.369 2184502
67. Relevance of the inoculum effect of antibiotics in the outcome of experimental infections caused by Escherichia coli. Soriano F, Ponte C, Santamaria M, Jimenez-Arriero M, J Antimicrob Chemother 1990 25 4 621 627 10.1093/jac/25.4.621 2190971
68. Bacterial concentrations in pus and infected peritoneal fluid-implications for bactericidal activity of antibiotics. Konig C, Simmen HP, Blaser J, J Antimicrob Chemother 1998 42 2 227 232 10.1093/jac/42.2.227 9738841
69. Multiplex PCR assays for the detection of clinically relevant antibiotic resistance genes in staphylococci isolated from patients infected after cardiac surgery: The ESPRIT Trial. Martineau F, Picard FJ, Grenier L, Roy PH, Ouellette M, Bergeron MG, J Antimicrob Chemother 2000 46 4 527 534 10.1093/jac/46.4.527 11020248
70. Multiplex PCR assay for simultaneous detection of nine clinically relevant antibiotic resistance genes in Staphylococcus aureus. Strommenger B, Kettlitz C, Werner G, Witte W, J Clin Microbiol 2003 41 9 4089 4094 10.1128/JCM.41.9.4089-4094.2003 12958230
71. Multiplex PCR for simultaneous detection of macrolide and tetracycline resistance determinants in streptococci. Malhotra-Kumar S, Lammens C, Piessens J, Goossens H, Antimicrob Agents Chemother 2005 49 11 4798 4800 10.1128/AAC.49.11.4798-4800.2005 16251336
72. Rapid molecular detection of tuberculosis and rifampin resistance. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD, N Engl J Med 2010 363 11 1005 1015 10.1056/NEJMoa0907847 20825313
73. Beta-lactamase genes of the penicillin-susceptible Bacillus anthracis Sterne strain. Chen Y, Succi J, Tenover FC, Koehler TM, J Bacteriol 2003 185 3 823 830 10.1128/JB.185.3.823-830.2003 12533457
74. Photodynamic therapy: a new antimicrobial approach to infectious disease? Hamblin MR, Hasan T, Photochem Photobiol Sci 2004 3 5 436 450 10.1039/b311900a 15122361
75. Photodynamic therapy in the treatment of microbial infections: basic principles and perspective applications. Jori G, Fabris C, Soncin M, Ferro S, Coppellotti O, Dei D, Fantetti L, Chiti G, Roncucci G, Lasers Surg Med 2006 38 5 468 481 10.1002/lsm.20361 16788934